Enterprise Value
3.964B
Cash
625.7M
Avg Qtr Burn
-155.7M
Short % of Float
16.34%
Insider Ownership
13.63%
Institutional Own.
96.76%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Empaveli (systemic pegcetacoplan) (APL-2) Details Paroxysmal nocturnal hemoglobinuria | Approved Quarterly sales | |
SYFOVRE™(Intravitreal pegcetacoplan) Details Geographic atrophy, Age-related macular degeneration | Approved Quarterly sales | |
Systemic pegcetacoplan (APL-2) Details Cold agglutinin disease | Phase 3 Data readout | |
Systemic pegcetacoplan (APL-2) Details Immune complex membranoproliferative glomerulonephritis, C3 Glomerulopathy | Phase 3 Data readout | |
Systemic pegcetacoplan (APL-2) Details Hematopoietic stem cell transplantation thrombotic microangiopathies | Phase 2 Data readout | |
Intravenous APL-9 Details ARDS (Acute respiratory distress syndrome), TMA (Thrombotic microangiopathies) | Failed Discontinued | |
Systemic pegcetacoplan (APL-2) Details Amyotrophic lateral sclerosis | Failed Discontinued |